As of 21 Sept 2026, Mangalam Drugs and Organics Ltd share price is ₹32.96. The stock opened at ₹32.96 and had closed at ₹34.24 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹22.70 and a high of ₹85.99. In terms of performance, Mangalam Drugs and Organics Ltd share price has increased by 14.98% over the past six months and has decreased by 54.70% over the last year.
MANGALAM Stock Price Chart
Mangalam Drugs and Organics Ltd Overview
About MANGALAM
Mangalam Drugs and Organics in the manufacture and sale of Active Pharmaceutical Ingredients (API) for various therapeutic segments viz. Anti-Malaria, Anti-Retrovirat, Anti-Hypertensive etc. It is the only API company globally to qualify under the Bill Clinton Foundation for supply of Anti-Malarial drugs and is amongst the 8 players globally (6 Formulators and 2 API players) with WHO prequalification for Anti-Malaria APIs- Artemether and Lumefantrine.
Mangalam Drugs and Organics Ltd Historical Performance
Mangalam Drugs and Organics Ltd Fundamentals
Mangalam Drugs and Organics Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 232.89 | 318.73 | 368.69 | 372.69 | 451.16 |
| EBITDA | -13.94 | 36.30 | 17.49 | 26.16 | 49.14 |
| Net Profit | -43.81 | 6.92 | -9.05 | 1.27 | 19.66 |
| EPS | -27.68 | 4.37 | -5.72 | 0.80 | 12.42 |
Mangalam Drugs and Organics Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 32.62 |
| Resistance 1 (R1) | 35.42 |
| Pivot Point | 33.81 |
MANGALAM Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| Govardhan M Dhoot | Chairman & Managing Director |
| Brijmohan Dhoot | E D & Wholetime Directorector |
| Nidhi S. Mundada | Non Executive Independent Director |
Mangalam Drugs and Organics Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,868.90+1.72% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,410.50+0.38% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,970.00+2.69% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Mangalam Drugs and Organics Ltd today is ₹32.96 on NSE and ₹32.96 on BSE.
- The 52-week high of Mangalam Drugs and Organics Ltd is ₹85.99, while the 52-week low is ₹22.70.
- The current market capitalisation of Mangalam Drugs and Organics Ltd is approximately ₹54 crore.
- The P/E (Price-to-Earnings) ratio of Mangalam Drugs and Organics Ltd is -1.50. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Mangalam Drugs and Organics Ltd is 0.39. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Mangalam Drugs and Organics Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for MANGALAM on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Mangalam Drugs and Organics Ltd has delivered a return of approximately -66.69%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Mangalam Drugs and Organics Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 35.65% promoters, 0.11% FIIs, 0.00% DIIs, and 60.51% public shareholders.
Download TradeMobi App
- Real-Time Market Data
- Advanced Trading Tools
- Expert-Backed Research
